Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $94.68 USD
Change Today -2.54 / -2.61%
Volume 1.9M
As of 8:04 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

Novartis AG, through its subsidiaries, specializes in the research, development, manufacture, and marketing of a range of healthcare products. Continuing Operations The company’s continuing operations include the following: Pharmaceuticals, Alcon, and Sandoz. PHARMACEUTICALS The Pharmaceuticals division offers patent-protected medicines to patients and physicians. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented pharmaceuticals in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. Products Oncology Gleevec/Glivec (imatinib mesylate/imatinib) is a kinase inhibitor approved to treat patients with metastatic and/or unresectable KIT (CD117) positive (KIT+) gastrointestinal stromal tumors (GIST), as an adjuvant treatment for certain adult patients following resection of KIT+ GIST, and as a targeted therapy for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML). Gleevec/Glivec is available in approximately 120 countries. Gleevec/Glivec is also approved in the U.S. and the EU to treat dermatofibrosarcoma protuberans, a rare solid tumor; hypereosinophilic syndrome; and myelodysplastic/myeloproliferative diseases and other rare blood disorders. In the U.S., Gleevec is also approved for aggressive systemic mastocytosis. Gleevec/Glivec has received approvals in 68 countries as a post-surgery (adjuvant setting) therapy for certain adult patients with KIT+ GIST. Sandostatin SC and Sandostatin LAR (long-acting release) (octreotide acetate/octreotide acetate for injectable suspension) is a somatostatin analogue indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Additionally, Sandostatin LAR is approved in 50 countries for treatment of patients with advanced neuroendocrine tumors of the midgut or unknown primary tumor location. Afinitor and Afinitor Disperz/Votubia (everolimus) is an oral inhibitor of the mTOR pathway. Afinitor is approved in approximately 100 countries including the U.S., the EU member states and Japan for advanced renal cell carcinoma following vascular endothelial growth factor-targeted therapy. Afinitor is also approved in approximately 85 countries, including the U.S., the EU and Japan for the treatment of advanced pancreatic neuroendocrine tumors. In addition, Afinitor is approved in approximately 90 countries for advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+/HER2– breast cancer). Everolimus is also approved in approximately 80 countries, including in the U.S. as Afinitor and in the EU as Votubia to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) and in approximately 70 countries for the treatment of adult patients with renal angiomyolipomas and TSC who do not require immediate surgery. Everolimus, the active ingredient in Afinitor, is also available under the trade names Zortress/Certican for use in transplantation in the U.S. and the EU, respectively, and is exclusively licensed to Abbott and sublicensed to Boston Scientific for use in drug-eluting stents. Tasigna (nilotinib) is a signal transduction inhibitor of the BCR-ABL tyrosine kinase. Tasigna is approved in approximately 110 countries to treat patients with Ph+ CML in the chronic and/or accelerated phase who are resistant or intolerant to existing treatment, including Gleevec/Glivec. It is also approved in approximately 85 markets, including the U.S., the EU member states, Switzerland and Japan, to treat newly diagnosed patients in the chronic phase. Exjade (deferasirox) is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older. Exjade is approved in approximately 100 countries, includ

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $94.68 USD -2.54

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan plc $294.21 USD -9.53
Amgen Inc $147.46 USD -4.32
Gilead Sciences Inc $101.49 USD -3.58
Johnson & Johnson $92.09 USD -1.89
Nestle SA SFr.70.70 CHF +0.60
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 24.8x
Price/Sales 4.6x
Price/Book 3.0x
Price/Cash Flow 13.4x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.